230 related articles for article (PubMed ID: 28855356)
1. Phase I Study of a Poxviral TRICOM-Based Vaccine Directed Against the Transcription Factor Brachyury.
Heery CR; Palena C; McMahon S; Donahue RN; Lepone LM; Grenga I; Dirmeier U; Cordes L; Marté J; Dahut W; Singh H; Madan RA; Fernando RI; Hamilton DH; Schlom J; Gulley JL
Clin Cancer Res; 2017 Nov; 23(22):6833-6845. PubMed ID: 28855356
[No Abstract] [Full Text] [Related]
2. Analyses of recombinant vaccinia and fowlpox vaccine vectors expressing transgenes for two human tumor antigens and three human costimulatory molecules.
Tsang KY; Palena C; Yokokawa J; Arlen PM; Gulley JL; Mazzara GP; Gritz L; Yafal AG; Ogueta S; Greenhalgh P; Manson K; Panicali D; Schlom J
Clin Cancer Res; 2005 Feb; 11(4):1597-607. PubMed ID: 15746065
[TBL] [Abstract][Full Text] [Related]
3. Enhanced activation of rhesus T cells by vectors encoding a triad of costimulatory molecules (B7-1, ICAM-1, LFA-3).
Shankar P; Schlom J; Hodge JW
Vaccine; 2001 Dec; 20(5-6):744-55. PubMed ID: 11738738
[TBL] [Abstract][Full Text] [Related]
4. Vaccine therapy of established tumors in the absence of autoimmunity.
Hodge JW; Grosenbach DW; Aarts WM; Poole DJ; Schlom J
Clin Cancer Res; 2003 May; 9(5):1837-49. PubMed ID: 12738742
[TBL] [Abstract][Full Text] [Related]
5. Comparative analysis of MVA-CD40L and MVA-TRICOM vectors for enhancing the immunogenicity of chronic lymphocytic leukemia (CLL) cells.
Litzinger MT; Foon KA; Tsang KY; Schlom J; Palena C
Leuk Res; 2010 Oct; 34(10):1351-7. PubMed ID: 20122733
[TBL] [Abstract][Full Text] [Related]
6. Enhancing the potency of peptide-pulsed antigen presenting cells by vector-driven hyperexpression of a triad of costimulatory molecules.
Hodge JW; Grosenbach DW; Rad AN; Giuliano M; Sabzevari H; Schlom J
Vaccine; 2001 May; 19(25-26):3552-67. PubMed ID: 11348723
[TBL] [Abstract][Full Text] [Related]
7. A triad of costimulatory molecules synergize to amplify T-cell activation in both vector-based and vector-infected dendritic cell vaccines.
Schlom J; Sabzevari H; Grosenbach DW; Hodge JW
Artif Cells Blood Substit Immobil Biotechnol; 2003 May; 31(2):193-228. PubMed ID: 12751840
[TBL] [Abstract][Full Text] [Related]
8. Phase 1 open-label trial of intravenous administration of MVA-BN-brachyury-TRICOM vaccine in patients with advanced cancer.
DeMaria PJ; Lee-Wisdom K; Donahue RN; Madan RA; Karzai F; Schwab A; Palena C; Jochems C; Floudas C; Strauss J; Marté JL; Redman JM; Dombi E; Widemann B; Korchin B; Adams T; Pico-Navarro C; Heery C; Schlom J; Gulley JL; Bilusic M
J Immunother Cancer; 2021 Sep; 9(9):. PubMed ID: 34479925
[TBL] [Abstract][Full Text] [Related]
9. Modified vaccinia virus ankara recombinants are as potent as vaccinia recombinants in diversified prime and boost vaccine regimens to elicit therapeutic antitumor responses.
Hodge JW; Poole DJ; Aarts WM; Gómez Yafal A; Gritz L; Schlom J
Cancer Res; 2003 Nov; 63(22):7942-9. PubMed ID: 14633725
[TBL] [Abstract][Full Text] [Related]
10. Vector-based vaccine/cytokine combination therapy to enhance induction of immune responses to a self-antigen and antitumor activity.
Aarts WM; Schlom J; Hodge JW
Cancer Res; 2002 Oct; 62(20):5770-7. PubMed ID: 12384537
[TBL] [Abstract][Full Text] [Related]
11. Phase I study of sequential vaccinations with fowlpox-CEA(6D)-TRICOM alone and sequentially with vaccinia-CEA(6D)-TRICOM, with and without granulocyte-macrophage colony-stimulating factor, in patients with carcinoembryonic antigen-expressing carcinomas.
Marshall JL; Gulley JL; Arlen PM; Beetham PK; Tsang KY; Slack R; Hodge JW; Doren S; Grosenbach DW; Hwang J; Fox E; Odogwu L; Park S; Panicali D; Schlom J
J Clin Oncol; 2005 Feb; 23(4):720-31. PubMed ID: 15613691
[TBL] [Abstract][Full Text] [Related]
12. Phase I study of a multitargeted recombinant Ad5 PSA/MUC-1/brachyury-based immunotherapy vaccine in patients with metastatic castration-resistant prostate cancer (mCRPC).
Bilusic M; McMahon S; Madan RA; Karzai F; Tsai YT; Donahue RN; Palena C; Jochems C; Marté JL; Floudas C; Strauss J; Redman J; Abdul Sater H; Rabizadeh S; Soon-Shiong P; Schlom J; Gulley JL
J Immunother Cancer; 2021 Mar; 9(3):. PubMed ID: 33762322
[TBL] [Abstract][Full Text] [Related]
13. A phase I study of recombinant (r) vaccinia-CEA(6D)-TRICOM and rFowlpox-CEA(6D)-TRICOM vaccines with GM-CSF and IFN-α-2b in patients with CEA-expressing carcinomas.
Duggan MC; Jochems C; Donahue RN; Richards J; Karpa V; Foust E; Paul B; Brooks T; Tridandapani S; Olencki T; Pan X; Lesinski GB; Schlom J; Carson Iii WE
Cancer Immunol Immunother; 2016 Nov; 65(11):1353-1364. PubMed ID: 27581603
[TBL] [Abstract][Full Text] [Related]
14. Phase I Trial of a Modified Vaccinia Ankara Priming Vaccine Followed by a Fowlpox Virus Boosting Vaccine Modified to Express Brachyury and Costimulatory Molecules in Advanced Solid Tumors.
Collins JM; Donahue RN; Tsai YT; Manu M; Palena C; Gatti-Mays ME; Marté JL; Madan RA; Karzai F; Heery CR; Strauss J; Abdul-Sater H; Cordes L; Schlom J; Gulley JL; Bilusic M
Oncologist; 2020 Jul; 25(7):560-e1006. PubMed ID: 31876334
[TBL] [Abstract][Full Text] [Related]
15. Enhanced activation of human T cells via avipox vector-mediated hyperexpression of a triad of costimulatory molecules in human dendritic cells.
Zhu M; Terasawa H; Gulley J; Panicali D; Arlen P; Schlom J; Tsang KY
Cancer Res; 2001 May; 61(9):3725-34. PubMed ID: 11325845
[TBL] [Abstract][Full Text] [Related]
16. Enhanced activation of T cells by dendritic cells engineered to hyperexpress a triad of costimulatory molecules.
Hodge JW; Rad AN; Grosenbach DW; Sabzevari H; Yafal AG; Gritz L; Schlom J
J Natl Cancer Inst; 2000 Aug; 92(15):1228-39. PubMed ID: 10922408
[TBL] [Abstract][Full Text] [Related]
17. Immunological targeting of tumor cells undergoing an epithelial-mesenchymal transition via a recombinant brachyury-yeast vaccine.
Hamilton DH; Litzinger MT; Jales A; Huang B; Fernando RI; Hodge JW; Ardiani A; Apelian D; Schlom J; Palena C
Oncotarget; 2013 Oct; 4(10):1777-90. PubMed ID: 24125763
[TBL] [Abstract][Full Text] [Related]
18. Chronic lymphocytic leukemia (CLL) cells genetically modified to express B7-1, ICAM-1, and LFA-3 confer APC capacity to T cells from CLL patients.
Litzinger MT; Foon KA; Sabzevari H; Tsang KY; Schlom J; Palena C
Cancer Immunol Immunother; 2009 Jun; 58(6):955-65. PubMed ID: 19009294
[TBL] [Abstract][Full Text] [Related]
19. A Phase I Dose-Escalation Trial of BN-CV301, a Recombinant Poxviral Vaccine Targeting MUC1 and CEA with Costimulatory Molecules.
Gatti-Mays ME; Strauss J; Donahue RN; Palena C; Del Rivero J; Redman JM; Madan RA; Marté JL; Cordes LM; Lamping E; Orpia A; Burmeister A; Wagner E; Pico Navarro C; Heery CR; Schlom J; Gulley JL
Clin Cancer Res; 2019 Aug; 25(16):4933-4944. PubMed ID: 31110074
[TBL] [Abstract][Full Text] [Related]
20. Vector-driven hyperexpression of a triad of costimulatory molecules confers enhanced T-cell stimulatory capacity to DC precursors.
Rad AN; Schlom J; Hodge JW
Crit Rev Oncol Hematol; 2001; 39(1-2):43-57. PubMed ID: 11418301
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
